MedTrace Logo

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07759245 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 606

Last updated 2026-08-12

No results posted yet for this study

Summary

The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Brenipatide

Brenipatide administered SC

DRUG

Placebo

Placebo administered SC

DRUG

Standard of Care

SOC

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-05-31
Completion
2028-11-30
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Austria
  • Canada
  • China
  • Czechia
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Japan
  • Mexico
  • Poland
  • Puerto Rico
  • Romania
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07759245 on ClinicalTrials.gov